Abstract 3 - Dr. Chatti Kaouthar: Uncommon Case of Orbital Metastasis Secondary to Follicular Thyroid Carcinoma: Good Outcome after Radio-Iodine Therapy

**K. Chatti, N. Essabbah, H. Regaieg, S. Boughattas, R. Sfar, M. Nouiram, T. Kamoun, H. Charfi, M. Guezguez, N. Ayachi, H. Essabbah**

Department of Nuclear Medicine, University Hospital of Sahloul, Sousse, Tunisia

**Objective:** We present here an uncommon case of orbital metastasis secondary to vesicular thyroid carcinoma treated with radio-iodine.

**Materials and Methods:** Case report.

**Results:** In 2002, a 62 old woman had developed a right exophthalmia with decrease in visual acuity. CT concluded to intra-orbital tumoral process. MRI was impossible to underwent because of the body weight of the patient. Biopsy concluded to a vesicular thyroid carcinoma metastasis. The patient undergone thyroidectomy and partial metastasis resection. Thyroglobulin (Tg) was high (509 ng/ml). She underwent regular IRA-therapy activities of 3.7 GBq every 4 or 6 months. She had had 44.4 GBq 131I. Regular hemogram control was always normal. Visual acuity had normalized. Tg decreased rapidly in the first 2 years, then decreased slowly. In 2013, Tg T4 off was 14 ng/ml and Tg T4 on was 2 ng/ml. After discussion with the patient, we decided to stop IRA therapy and to continue survey by Tg, CT and clinical exam under thyroid hormonotherapy. Two years after, the patient was going well, MRI and Tg T4 on were stable.

**Conclusions:** Follicular thyroid bone metastasis had a bad prognosis, but when the tumour is localized and after decreasing mass tumour, radio-iodine therapy can be efficient.

**Address for correspondence:**

Dr. Kaouthar Chatti, Route De Ceinture, 4054, Sahloul, Sousse, Tunisia. E-mail: <Kaouthar.chatti@gmail.com>

Abstract 4 - Milovan Matovic: Telemedicine: New Approach to On-Line Monitoring of Patients with Differentiated Thyroid Carcinomas and Neuroendocrine Tumors Treated with High Doses of Radionuclide Therapy

**Milovan Matović, Marija Jeremić, Vlade Urošević, Miroslav Ravlić, Marina Vlajković, Zoran Tasic**

Department of Nuclear Medicine, Clinical Center Kragujevac and Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

**Objective:** Following RNT of DTC and NET, patients must usually remain hospitalised in special premises with restricted access, until radiation in their body drops below the legally defined effective dose limit. During hospitalisation, these patients may experience complications or adverse reactions, so it is of vital importance that doctors and nurses have audio-visual contact with patients, and follow-up their vital functions as well as the decline of radiation in their body. Telemedicine could be a potential solution for monitoring such cases.

**Materials and Methods:** We have developed a telemedicine system which encompasses three important aspects: Continuous on-line remote monitoring of the patient\'s vital functions and radiation level in the patient\'s body, and video surveillance of the patient\'s room. Our system consists of custom-developed hardware/software solutions for data acquisition and processing, and enables communication via the Internet and related services.

**Results:** Our custom-developed telemonitoring system has been in use for the last 4 years, helping us treat more than 300 patients who received RNT. It has helped us detect and react to various instances of patients' vital function or behavioural changes. Furthermore, the continuous monitoring of radiation levels in the patient\'s body achieved with our own custom-developed software has helped us predict when the patient will be released from the hospital and optimise the use of limited hospital space allotted to radionuclide therapy.

**Conclusions:** Four years of experience in telemonitoring patients who receive radionuclide therapy suggest that this technological aspect of the treatment ensures a high level of safety for the patient, as well as a significant reduction of overall treatment costs.

**Address for correspondence:**
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Abstract 5 - Zvezdana Rajkovaca: Outcome of Low Radioiodine Dose for the Postoperative Ablation of Thyroid Remnant in Patients with Low-Risk Differentiated Thyroid Carcinoma

**Zvezdana Rajkovaca, Sonja Bobic, Davor Golic, Jovana Brstilo**

Department of Nuclear Medicine, Clinical Centre, Banja Luka, Bosnia and Herzegovina

**Objective:** This study aimed to evaluate the success rate of low dose radioiodine remnant ablation (RRA) on the outcome of low-risk differentiated thyroid carcinoma (DTC) patients.

**Materials and Methods:** We retrospectively analyzed 512 patients, 143 (27.93%) of whom received low dose RAI, 1724 ± 270 MBq. The patients consisted of 14 males and 129 females, mean age 47.7 ± 12.9 years, 93 stage pT1N0, 35 pT2N0 and 15 pT3N0.

**Results:** Successful RRA was achieved in 131 patients (91.6%). 11 patients (7.69%) needed additional RAI treatment. Only 1 patient (0.7%) needed RAI treatment three times.

**Conclusions:** Good outcomes were achieved with the low dose of 1724 ± 270 MBq RRA.

**Address for correspondence:**
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Abstract 9 - Sonya Sergieva: Role of 131I Single-Photon Emission Computerized Tomography Scintigraphy in Posttreatment Radioiodine Imaging of Patients with Differentiated Thyroid Carcinoma

**S. Sergieva, T. Hadjieva, M. Dimcheva**

Sofia Cancer Center, Sofia, Bulgaria

**Objective:** 131I single-photon emission computerized tomography (SPECT-CT) allows correct anatomic localization and identification of iodine-avid foci, which can be characterized as benign, in remnant thyroid tissue or physiological distribution in normal structures, or as malignant metastatic lesions.

**Materials and Methods:** Target SPECT-CT studies and 131I-whole body scan were performed in 135 patients with differentiated thyroid carcinoma 5 days after radioiodine therapy.

**Results:** SPECT-CT images provide differential diagnosis of the most of malignant (lymphogenic, bone and lung) metastases and equivocal (benign or physiological) foci in the 131I WBSs and can discover 131I non-avid secondary lesions, reducing false positive results and inconclusive studies.

**Conclusions:** Fusion images can detect radioactive metastases, residual or recurrent disease which led for further prescribed 131I therapy or to modification of patient management in order to avoid unnecessary radioiodine treatment and to perform surgical excision or external beam radiation therapy.

**Address for correspondence:**
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Abstract 10 - Prof. Majdi Zein: Optimization of Radio-Iodine 131 Dose in Treatment of Children with Diffuse Lung Metastasis from Thyroid Carcinoma-Local Experience at Al- Assad University Hospital, Damascus

**Majdi Zein**

Al-Assad University Hospital, Damascus, Syria

**Objective:** Children with diffuse lung metastasis considered to be a challenge for radio-Iodine treatment, due to critical difference between the effective treatment dose and side effects expected after long-term treatment with several radio-iodine 131 doses.

**Materials and Methods:** 11 children suffering from diffuse lung metastasis from thyroid carcinoma were admitted to the Department of Nuclear Medicine at Al-Assad University Hospital, Damascus at the period between May 2010 and March 2012. Age of patients was from 7 to 14 years, five males and six Females. General medical evaluation was done for all patients physically and psychiatrically. Also, WBC -- blood test for renal function-thyoglobulin level-ultrasound image for the anterior neck and chest X-ray were obtained. After discontinue of thyroid hormone for 3--4 weeks and withdrawing foods containing iodine for enough time a doses of radio-active iodine between 30 and 60 mCi (depending at the patient age and weight) were given at the department, admission prolonged for 3--5 days according to residual activity in the body. Whole body scans were performed at the 5^th^ day after radio-iodine treatment dose. Six months after radio-iodine treatment second total evaluation was done for all patients. All patients showed residual metastasis at the lungs, without any residual tissue at the neck. According to initial results all patients were given a second radioactive-iodine dose of 70--100 mCi. Another repeated doses were given according to results of general evaluation until total remission of the disease in five children. No significant side effect nor respiratory symptoms were noted except for some dyspinia in three children.

**Results:** 7 of 11 patients revealed total remission after three to five cycles of radio-iodine treatment including negative iodine WBS and thyroglobulin level around zero, while four patients showed no significant improvement after the fifth dose. Where the whole body iodine whole body scan still positive in the lungs, also Thyroglobulin level remained in high levels with mild decrease writhen two month after treatment.

**Conclusions:** Diffuse lung metastasis from thyroid cancer can be treated safely using a doses of radioactiveiodine between 70 and 100 mCi without significant side effects, and the treatment overall results were acceptable.

**Address for correspondence:**
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Abstract 11 - Dr. Faria Nasreen: Outcome of Well-differentiated Thyroid Carcinoma Patients Receiving a Cumulative Doses of ≥600 mCi I-131

**Faria Nasreen, Nurun Nahar, Faridul Alam**

National Institute of Nuclear Medicine and Allied Sciences, Dhaka, Bangladesh

**Objective:** The aim of the study was to see the outcome of patients with well differentiated thyroid carcinoma receiving a cumulative doses (CDs) of ≥600 mCi I-131.

**Materials and Methods:** A retrospective study of 72 patients with well differentiated thyroid carcinoma (DTC) receiving a CDs of ≥600 mCi I-131 in the National Institute of Nuclear Medicine and Allied Sciences, Dhaka during the period of January1994 up to December 2007 was carried out. All patients were treated by thyroidectomy followed by radioiodine therapy. Status on last follow up was noted to estimate the survival rate.

**Results:** A total of 38 patients had papillary carcinoma, eight had follicular variant of papillary carcinoma and 26 had follicular carcinoma. Age range at diagnosis was nine to 72 years. There were 22 males and 50 females giving a M: F ratio of about 1:2. Among the 72 patients 25 patients had lymph node metastases, eight had lung metastases and 20 had bone metastases at presentation. Twenty one patients died during the whole observation period and 20 of them were cancer related. Two patients developed second malignancy.

**Conclusions:** DTC patients having bone metastases, follicular variant and improper initial thyroid surgery do not have a favourable outcome in spite of high CDs.

**Address for correspondence:**
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Abstract 12 - Dr. Masha Maharaj: Tailoring Therapy for Benign Thyroid Disease in Private Practice

**Masha Maharaj**

Department of Nuclear Medicine, Westridge PET/CT Oncology Centre, Durban, South Africa

**Objective:** Targeted radionuclide therapy has the potential to selectively deliver radiation to diseased cells with minimal toxicity to surrounding tissues. The cost of radiopharmaceutical, travel, pre- and post-management have serious implications on the private patient\'s pocket. The aim is to reduce the costs by providing effective single dose therapy outcome. The average cost for benign thyroid therapy inclusive of pre and post management is an estimate R20000 per patient. This comes out of the patients own Medical Aid savings or salary. Previously in this region patients were treated for Benign thyroid disease by Oncologists. Thyroid uptake scans were not included in this protocol. The doses applied were 148 Mbq followed by 296 MBq and 444 MBq, depending on the patient\'s clinical response. In retrospect, at least 50% of patients were administered therapy doses upto the 2^nd^ and 3^rd^ doses.

**Materials and Methods:** 10 patients were referred to our centre for thyroid uptake scans and subsequently for benign thyroid therapy for hyperthyroidism. Five criteria were used to tailor the dose: Size of gland, distribution of activity, percentage thyroid uptake, sex of patient, age of patient. Using these criteria the minimum dose given would be 185 MBq and maximum 555 MBq. Concurrent control studies were not done. Response of therapy was confirmed clinically and on biochemistry.

**Results:** There was confirmed single dose response in 9 of the 10 patients. The one patient confirmed response after the 2^nd^ capsule.

**Conclusions:** There appears to be a benefit in tailoring radionuclide therapy for benign thyroid disease.

**Address for correspondence:**
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Abstract 13 - Dr. Raihan Hussain: Outcome of Strontium-90 Irradiation on Conjunctival Squamous Cell Carcinoma: A 6-year Experience

**Raihan Hussain, Sadia Sultana, Zeenat Jabin, Rahima Perveen, Khokon Kumar Nath, Faridul Alam**

National Institute of Nuclear Medicine and Allied Sciences, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh

**Objective:** The aim of the study was to evaluate the efficacy and risk of complications of Strontium (Sr-90) irradiation on post-operative conjunctival squamous cell carcinoma (CSCC).

**Materials and Methods:** A retrospective study on 26 patients (22 M, 4 F) receiving post-operative beta irradiation from April 2008 to March 2014 was done. All received 130 Gy (except one with 60 Gy) to postoperative sclera surface in five fractions by hand-held surface applicator. Follow-ups were done at 1 week, 1 month, 6 month and 1 year interval.

**Results:** Three had recurrences within 1 year. Shortterm self-limiting complications included conjunctivitis, photophobia, watering of eyes etc. 2 developed cataract as long-term complications.

**Conclusions:** With excellent results having minimal morbidity, we continue to encourage use of Sr-90 as a successful treatment modality for CSCC.

**Address for correspondence:**
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Abstract 14 - Prof. Lutfun Nisa: Status and Evolution of Radionuclide Therapy in Bangladesh

**Lutfun Nisa**

National Institute of Nuclear Medicine and Allied Science, Shahbag, Dhaka, Bangladesh

**Objective:** To present the status of radionuclide therapy in Bangladesh.

**Materials and Methods:** Retrospective analysis of radionuclide therapy in patients with different diseases are noted. Proposed protocol for targeted alpha therapy in Bangladesh will be discussed.

**Results:** Differentiated thyroid carcinomas have been treated with 131- I since 1980 at National Institute of Nuclear Medicine and Allied Science. So far about 5000 patients received 131-I therapy. In the past, P-32 was used for treatment of polycythemia vera. Strontium-90 is still used in pterygium. Bangladesh recently obtained ethical clearance for clinical phase 1 trial of MUC1 receptor positive cancers. The project will optimize key parameters of TAT including maximum tolerance dose for higher rate of tumor control.

**Conclusions:** The proposed trial for TAT in MUC1 receptor positive cancers will be highlighted in this presentation.

**Address for correspondence:**
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Abstract 15 - Bonan Mendoza: Radioactive Iodine 131 Therapy: A Treatment Option for Diffuse and Nodular Non-toxic Goiter

**Bonan Achiles G. Mendoza**

Mary Mediatrix Mendical Center, Lipa, Batangas, Philippines

**Objective:** The aim of the study is to describe the effectiveness of radioactive iodine 131 therapy in the treatment of diffuse and nodular toxic goiter.

**Materials and Methods:** Patients record from the Goiter Clinic were re-examined. Those patients diagnosed with diffuse non-toxic goiter and nodular non-toxic goiter that were treated with radioactive iodine 131 were selected. The clinical profile and demographic features of these patients were documented. Thyroid volume, size and number of thyroid nodules before and after Radioactive Iodine treatment were compared.

**Results:** A total of 57 patients, 55 females and 2 males aged between 19 and 78 years old (mean: 48.40 ) seen in the Goiter Clinic who were treated with radioactive iodine 131 were included in the study. There were 9 patients with diffuse non-toxic goiter and 48 patients had nodular non-toxic goiter. Patients with diffuse nontoxic goiter were given a fixed dose of 15.0 mCi while fixed doses of 30.0 mCi were given to those patients with nodules. The mean TSH IRMA before Radioiodine administration was 1.50 uIU/ml. Follow up period was 3 months, 6 months and 1 year. Reduction of thyroid volume post-treatment was 31.70% while post-treatment nodule reduction was 35%, with disappearance of nodules in 18 patients. There was improvement of symptoms associated with the anterior neck mass. Replacement dose of levothyroxine were given to the patients who developed hypothyroidism.

**Conclusions:** Diffuse non-toxic and nodular non-toxic goiter can be effectively treated with radioactive iodine 131.

**Address for correspondence:**
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Abstract 17 - Dr. Zeenat Jabin: Outcome of 131-Radioactive Iodine Therapy in the Treatment of Childhood and Adolescent Thyrotoxicosis

**Zeenat Jabin, Nurun Nahar, Raihan Hussain**

National Institute of Nuclear Medicine and Allied Sciences, Shahbag, Dhaka-1000, Bangladesh

**Objective:** To evaluate the outcome of I-131 therapy in thyrotoxicosis in childhood and adolescence. **Materials and Methods:** This was a retrospective study of 32 thyrotoxic patients (10--17.9 years) who received I-131 therapy during January 2001 to December 2012 in the thyroid division of our institute. Gender, duration of antithyroid drug (ATD) treatment, hormonal status, RAIU, ultrasound, thyroid scan, dosage and number of therapies and post therapy thyroid status at 6 months were recorded.

**Results:** 32 patients (87.5% F, 12.5% M) treated with I-131 were analyzed to assess the effectiveness of therapy. All children and adolescents received single or multiple I-131 doses between 6 and 14 mCi. Six months after treatment, 31.25% of the patients were hyperthyroid, 25% euthyroid and 43.75% were hypothyroid. Of the 10 cases with hyperthyroidism, 8 needed a second dose and finally reached a hypothyroid state.

**Conclusions:** RAI treatment is safe and effective for childhood and adolescence thyrotoxicosis.
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Abstract 18 - Dr. Partha S. Choudhury: Early Radioiodine Ablation Post Thyroidectomy with Recombinant TSH Stimulation and its Impact on Performance Status, Versus Thyroxine Abstinence Protocol in Differentiated Thyroid Carcinoma: Initial Results of a Randomized Prospective Clinical Trial

**P. S. Choudhury, A. Pruthi, M. Gupta, A. K. Dewan^1^, T. Pradhan^1^, A. Goel^1^, V. Chauhan, V. Talwar^1^**

Departments of Nuclear Medicine and 1Surgical Oncology (Head and Neck Services), Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India

**Objective:** Feasibility and utility of using recombinant TSH (r-TSH) injection to facilitate ablation immediately post thyroidectomy and its impact on performance status compared to thyroxine abstinence.

**Materials and Methods:** Two thyrotropin stimulation methods used: r-TSH within 10--12 days postsurgery during one hospital stay (group I) and thyroxine abstinence for 4--5 weeks (group II). 18 years or older, total/near total thyroidectomy, pT1-T3, N0/N1 M0 included. Standard r-TSH protocol used (group I). Diagnostic whole body 131I scan followed by ablative dose of radioiodine in group II. 45--68 mCi radioiodine were used for ablation. Quality of life (QOL) assessment was done by standard ECOG criteria. Response assessed after 6 months by scintigraphy, neck ultrasonography and stimulated thyroglobulin. End points were rate of success of ablation and quality of life during and after ablation. Relevant statistical analysis was performed. The protocols were approved by the institutional review board (ethics committee).

**Results:** 29 patients of radioiodine ablation during March 2011--May 2013 were included in the analysis. 89% had papillary carcinoma. 12 (57.38 ± 14.85 years) and 17 (41.73 ± 12.87 years) randomized to group I and II respectively. Adequate TSH response was seen (\>80 µIU/ml). Avid 131I concentration in residual and no distant metastasis, seen in the post therapy scans in all. No statistically significant difference was seen in response rates between the groups. ECOG score 0--1 and 2--3 in group I and II respectively. There was statistically significant difference in QOL between the groups (*P* = 0.0005).

**Conclusions:** Ablation of residual thyroid tissue is feasible immediately post thyroidectomy by r-TSH stimulation with same outcome compared to the thyroxine withdrawal. No morbid symptoms of hypothyroidism post r-TSH stimulation resulted in better compliance, performance status and quality of life with patients being able to go back to their normal routine much earlier.
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Abstract 20 - Dr. Khalid Makhdomi: Efficacy of Fixed High Dose (30 mCi) Iodine-131 Therapy for Solitary Toxic Thyroid Nodule

**Khalid Bashir Makhdomi**

Aga Khan University Hospital, Nairobi, Kenya

**Objective:** To determine the effectiveness of a fixed high dose (30 mCi) iodine-131 therapy for treatment of solitary toxic thyroid nodules. **Materials and Methods:** Twenty-seven consecutive patients, presenting with hyperthyroidism, whose 99mTcO4 thyroid scan revealed solitary thyroid nodules, and who had undergone high dose (30 mCi) iodine-131 therapy, with follow-up of a minimum 1 year, were recruited for this retrospective study. The therapies had been done at our institution from January 2008 to December 2012. The technetium thyroid uptake pre-treatment was noted for all patients. The biochemical status, freeT4 and TSH, at the end of 1 year was noted.

**Results:** The technetium thyroid uptake ranged from 3.7% to 9.8%, with a mean of 5.9%. Twenty-two (81.5%) of the patients were biochemically euthyroid at the end of 1-year. Three patients (11.1%) had documented hypothyroidism between 7 and 10 months after the therapy and were on thyroxine supplementation. Two patients (7.4%) had continued to stay biochemically hyperthyroid at the end of 1 year. Both were on antithyroid medications, and both eventually had surgeries.

**Conclusions:** Empirical, fixed high dose (30 mCi) iodine-131 therapy for solitary toxic thyroid nodules produces very good cure rates with very modest incidence of hypothyrodism, and should hence be considered as an effective option for management.
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Abstract 21 - Dr. Masha Maharaj: A Case of Unsuspected Sarcoidosis on Positron Emission Tomography-- Computed Tomography in Ovarian Carcinoma

**Masha Maharaj, Nisaar Korowlay^1^**

Department of Nuclear Medicine, Westridge PET/CT Oncology Centre, Durban, ^1^Division of Nuclear Medicine, Tygerberg Hospital Stellenbosch University, South Africa

**Introduction**: A 59-year-old female presents with stage 1 ovarian carcinoma. Histology demonstrates a mucinous papillary tumour. Positron emission tomography-- computed tomography scan was indicated for staging and surveillance.

**Results:** Multiple fluorodeoxyglucose (FDG) avid bone and lung lesions were seen. The features suggestive of metastases. The clinical and primary staging was not consistent with the extent of FDG avid pathology. A biopsy of the left sacrum was done. Bone biopsy revealed non-caseating granulomatous tissue consistent with sarcoidosis.

**Conclusion:** The imaging features of sarcoidosis are diverse and can be seen on a variety of imaging techniques. Sarcoidosis or sarcoid reactions, which appear as FDG-avid lesions in oncologic patients, need to be differentiated from disseminated malignancies.
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Abstract 22 - Assoc Prof Marina Vlajkovic: The Role of Technetium-99m- Ethylenediamine-N, N'-Diacetic Acid/Hydrazinonicotinyl- Tyr3-Octreotide Somatostatin Receptor Scintigraphy in Selecting Thyroid Cancer Patients with Negative I-131 Scan and Rising Tyreoglobulin for Peptide Radioreceptor Therapy --Preliminary Results

**Marina Vlajković, Milena Rajić, Miloš Stević, Slobodan Ilić, Vesna Živković^1^, Aleksandar Karanikolić^2^, Milovan Matović^3^**

Faculty of Medicine and Center of Nuclear Medicine, ^1^Faculty of Medicine and Clinic of Physical Medicine, Rehabilitation and Prosthetics, ^2^Faculty of Medicine and Clinic for Surgery, Clinical Center Niš, University of Niš, Niš, ^3^Faculty of Medicine and Center of Nuclear Medicine, Clinical Center Kragujevac, University of Kragujevac, Šumadija, Serbia

**Objective:** The aim of this study is to present the results of somatostain receptor scintigraphy (SRS) using Tc- 99m-EDDA/HYNIC-TOC as a potential tool both for the detection of recurrences in patients with non-iodine avid differentiated thyroid carcinoma (DTC) and for the possible selection of these patients for peptide radioreceptor therapy (PRRT).

**Materials and Methods:** Five patients (33--70 year of age) with recurrent or persistent DTC as indicated by elevated tyreoglobulin (Tg) levels but negative iodine-131 posttherapy whole-body scans were submitted to SRS. In 3 out of 5 patients F18-FDG PET scan was performed.

**Results:** SRS was positive in 3 out of 5 patients, demonstrating 4 focal lesions in neck and mediastinal lymph nodes. Two out of 3 SRS positive patients were selected for 177Lu-DOTATATE PRRT. The others were indicated for chemo-and radiotherapy.

**Conclusion:** SRS with Tc-99m-EDDA/HYNIC-TOC might be a useful tool for the detection of recurrences and treatment planning in patients with non-iodine avid DTC.
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Abstract 23 - Raluca Mititelu: Use of 89Sr for Bone Pain Palliation in Patients with Prostate Cancer

**Mihaela-Raluca Mititelu, Catalin Mazilu, Sorin Mititelu, Eduard Danaila**

"Carol Davila" Central University Emergency Military Hospital, Bucharest, Romania

**Objective:** To analyze results of treatment with 89Sr performed in our department, at patients with metastatic bone pain.

**Materials and Methods:** We treated 43 patients with prostate adenocarcinoma and refractory bone pain from multiple osteoblastic metastasis. We administered 150 MBq, single dose in 32 cases; in 11 patients a second dose was administered at 4, 6 or 9 months. Evaluation of haematologic status was performed monthly.

**Results:** Significant pain relief was seen in 28 patients; 10 patients had moderate response, No response in 5. Most serious side effects were mild to moderate myelosuppression (in 31 patients - 72.09%) and pain flare (28 cases - 65.11%). **Conclusions:** 89Sr allows significant improvement of life quality in patients with osteoblastic metastasis, with controllable side effects and good compliance of patients.
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Abstract 24 - Dr. Emerita Andres Barrenechea: Efficacy of Radioiodine Treatment in Well-differentiated Thyroid Cancer in Children

**Emerita A. Barrenechea**

Veterans Memorial Medical Center, St. Luke\'s Medical Center, Quezon City, Philippines

**Objective:** Well-differentiated thyroid cancer in children is the third most common solid tumor malignancy and the most frequent endocrine malignancy in children. They are more aggressive at the time of diagnosis, with metastases and have a higher risk for recurrence. The objective of this paper is to determine the efficacy of radioiodine treatment after five to six years from therapy.

**Materials and Methods:** Fifteen (15) pediatric patients with a diagnosis of thyroid carcinoma, aged below 18 years of age were included in a six-year follow-up after treatment. They underwent thyroidectomy, followed by RAI ablation. The predominantly female population (74%) had papillary TCA (13 patients) and (2) had follicular. Nodal metastases were seen in 53% and lung metastases were seen in 20% of the cases.

**Results:** Of the 13 who underwent RAI ablation, 3 cases of lung metastases while two cases with lymph node metastases needed repeat treatment. On follow-up after an average of six years, all the 13 patients who underwent RAI ablation are doing well with the lifetime thyroid hormone treatment. The remaining two patients who did not undergo therapy succumbed on the 2nd and third year after diagnosis.

**Conclusion:** WDTCA in children is rare and the biological behavior differs from that of adults. Their presentation is quite aggressive and may be recurrent. Total or near total thyroidectomy with I-131 ablation reduces mortality and hence is efficacious.
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Abstract 25 - Dr. June-Key Chung: Development of Dual Modality Probe for Targeting Intracellular Human Telomerase Reverse Transcriptase using Tat Peptide-Conjugated Antibody

**June-Key Chung**

Department of Nuclear Medicine, Seoul National University, Seoul 110-711, Korea

**Objective:** Human telemorase reverse transcriptase (hTERT) is expressed in most of cancer cells, and considered as an important tumor biomarker. However, targeting hTERT is difficult due to its cellular location. We developed a new dual probe for optical and nuclear imaging to visualize intracellular hTERT proteins using Tat peptide-conjugated antibody.

**Materials and Methods:** Monoclonal antibodies for hTERT were conjugated with the Tat peptide, fluorescence dye (FPR648) and 64Cu-NOTA. HT29 (hTERT^+^) and U2OS (hTERT^−^) cells were imaged by confocal microscopy and live cell imaging, and analyzed by Tissue-FAXS. To visualize nuclear transport of hTERT, tumor cells were irradiated with 4 Gy of ionizing radiation Akt inhibitor with 2.5 uM concentration was treated to the tumor cells for blocking nuclear transport. Tumor xenografts were visualized using Maestro and PETBOX.

**Results:** Cellular penetration was improved by Tat peptide, and retention time was prolonged with this dual modality probe. The more fluorescence signals were detected in HT29 cells than in U2OS cells after 24 h. Strong positive fluorescence signal was observed in 78.54% of total HT29 cells. Interestingly, this probe could visualize nuclear transport of hTERT after radiation which is blocked by Akt inhibitor. Fluorescence and PET images of the mice clearly showed higher fluorescence signals and radioactivities in HT29 tumors than in U2OS tumors. In tissues, fluorescence signals were only detected in HT29 tumors.

**Conclusions:** We developed a new fluorescence/PET probe for visualizing the intracellular hTERT using the Tat conjugated antibody which improved cellular penetration. This system can be applied to visualize other intracellular proteins and also can be used to target intracellular biomarkers for therapeutic applications.
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Abstract 26 - Del Mundo, Karina Michaela: Outcome of Radioiodine Therapy in Patients with Benign Diffuse and Nodular Goiter

**Karina Del Mundo, Jasmine De Jesus, Juan Torres**

University of Santo Tomas Hospital, Espana Blvd, Philippines

**Objective:** This study investigates the consequences of I-131 treatment on thyroid function and size in a group of patients with nodular and diffuse goiter. The primary objective of the study is to compare thyroid size and function before and after RAI therapy. Secondary objective is to evaluate changes in subjective symptoms.

**Materials and Methods:** This is a prospective study of patients with nodular goiter selected for radioactive iodine therapy in a Tertiary Hospital from 2011 to 2012. All participating patients underwent both pre- and post- RAI therapy I-131 thyroid scans.

**Results:** In a significant number of patients, there was complete disappearance of nodules. There was clinical improvement of previously noted symptoms like anterior neck enlargement and obstructive symptoms. There was no recurrence or development of new nodules noted at the end of the study.

**Conclusions:** Radioactive iodine therapy is an effective and safe management that could be used as a primary therapy in patients with nodular non-toxic goiter.
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